Phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous and Non- Small Cell Lung Cancer harboring EGFR mutation who acquired resistance to prior gefitinib treatment (TAILORED-1 study)
Phase 2
Recruiting
- Conditions
- on-Small Cell Lung Cancer
- Registration Number
- JPRN-UMIN000006457
- Lead Sponsor
- Kyushu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Squamous cell carcinoma 2)Interstitial pneumonia or pulmonary fibrosis on chest CT scans 3) i)Brain metastasis expected bleeding ii)Patients with untreated Brain metastasis 4)Active severe comorbidity disease 5)History of hemoptysis 6)Uncontrollable hypertension 7)History of gastrointestinal perforation or diverticulitis or fistula 8)Scheduled operation 9)History of grave drug allergic reaction 10)Active concomitant malignancy 11)Pregnant or breast-feeding females 12)Inappopriate patients for this study by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression Free Survival
- Secondary Outcome Measures
Name Time Method Response Rate Disease Control Rate Overall Survival Safety